Nuvation Bio Inc.
NUVB- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811063
In the last 90 days, Nuvation Bio Inc. insiders filed 0 open-market purchases and 1 sale; 244 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; 3 superinvestors hold it, including Duquesne Family Office and Abrams Capital.
13F holders, Q2 2021
Institutional positions in Nuvation Bio Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- +26 vs. Q1 2021
- Shares held
- 148.0M
- +2.42M (+1.7%) vs. Q1 2021
- Total value
- $1.36B
- −$113.5M (−7.7%) vs. Q1 2021
- New holders
- 49
- 23 more added
- Sold out
- 23
- 16 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NUVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 244 | $1.33B |
| Q1 2026 | 233 | $947.4M |
| Q4 2025 | 224 | $1.89B |
| Q3 2025 | 203 | $817.8M |
| Q2 2025 | 182 | $439.1M |
| Q1 2025 | 161 | $364.9M |
| Q4 2024 | 160 | $526.0M |
| Q3 2024 | 154 | $428.6M |
| Q2 2024 | 148 | $447.0M |
| Q1 2024 | 124 | $490.1M |
| Q4 2023 | 116 | $202.7M |
| Q3 2023 | 125 | $183.4M |
| Q2 2023 | 124 | $250.2M |
| Q1 2023 | 129 | $228.2M |
| Q4 2022 | 127 | $267.9M |
| Q3 2022 | 122 | $317.5M |
| Q2 2022 | 120 | $503.2M |
| Q1 2022 | 117 | $837.0M |
| Q4 2021 | 105 | $1.32B |
| Q3 2021 | 98 | $1.50B |
| Q2 2021 | 99 | $1.36B |
| Q1 2021 | 73 | $1.48B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Nuvation Bio Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −1,000,000−100.0% | Sold out |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −800,000−100.0% | Sold out |
| Wellington Management Group LLP | 0 | $0 | 0.00% | −808,325−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| Ghost Tree Capital, LLC | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| RTW Investments, LP | 0 | $0 | 0.00% | −300,000−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −250,000−100.0% | Sold out |
| Cormorant Asset Management, LP | 0 | $0 | 0.00% | −234,445−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −159,162−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −78,177−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −49,635−100.0% | Sold out |
| Cannon Global Investment Management, LLC | 0 | $0 | 0.00% | −49,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −37,408−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −28,338−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −21,642−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −19,449−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −17,386−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −12,900−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −12,762−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −10,904−100.0% | Sold out |
| Lincoln National Corp | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Optimum Investment Advisors | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |